Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you are invested in Titan Medical Inc and want to know if you made the right choice in R&D Surgical Robotic companies, just look at TRXC, Trixie, Transenterix and see what they have done with their FDA APPROVED PRODUCT.
Titan Medical Inc, was the right call, just have to have patience b/c SINGLE PORT Surgical Robotics is the next generation, novel platform.
Backformore, there really is only three positions on this board and you have to decipher for yourself but they are:
1. Buyout/partnership/Acquisition - this is the position I hold and based off the research of myself and others regarding M&A, buyout. Long term view.
2. Shorters/day traders - the legal position to make money off a stock that behaves the way TMDI has. Very predictable and able to take a short position. Short term view
3. Somewhere in the middle, not sure what too make of Titan Medical. On the one hand, very predictable to this point and easily could trade in an out to sell at a high and buy back in at a low to increase share count. On the other hand, the shoe could drop at any second. A ton of coincidences that don't make sense, primary among them is "Why does Chad Zaring or Why does Medtronic let Chad Zaring go to a direct competitor of their upcoming surgical robotic platform announcement of Sept 24?"
Sept 24th is less then 20 days away, well within the Wash Sale rules that prohibit any seller of stock to buy back in within 30 days. IS IT WORTH THE RISK? IMO, not too sure, I haven't been able to come up with a good answer as to why Chad Zaring would leave the top post of Medtronic's future to go work with Titan.
SO INTUITIVE IS KING!!!!!!!!!!!!!!!!!!!!!!!!!
Question for the entire board:
IF any biggun wants to compete with Intuitive, will they need a SINGLE PORT surgical robotic platform?
Simple YES or NO to help tally the results would be much appreciated. I can post the tally's in a weeks time to see what this Titan Medical Inc Board thinks about that.
#TMDI
#SINGLEPORT
#SINGLE-PORT
#ROBOTICSURGERY
#SURGICALROBOTICS
#JNJ
#VERBSURGICAL
Very astute and closer than most....Titan has the goods....
The question is "Who wants a huge lead over the competition when it comes to Robotic Sugery?". To get there you will need Titan's SPORT SINGLE PORT Surgical robotic platform
#TMDI
#SINGLEPORT
#SINGLE-PORT
#ROBOTICSURGERY
#SURGICALROBOTICS
#JNJ
#VERBSURGICAL
Do want to point out that u most recently told people to sell at $1.20 and buy back in at 70 cents and people lost half their shares w that strategy
Great point, the company with the most to lose is Intuitive. SINGLE PORT is the future and to come in and buy Titan to completely lock down SINGLE PORT for 20 years would be priceless and should be priceless for ISRG. They should come in right now and pay to protect their existence.
Searching for what expert robotic surgeons were saying about Titan Medical and found this:
Lee Swanstrom, MD, FACS, Chief Innovation Officer of IHU Strasbourg, said, “I was pleased with my first experience with the SPORT system for applications in abdominal procedures. There are many patients undergoing general surgical procedures who could greatly benefit from a reduced number of incisions. Single-port robotic surgery can be a truly enabling solution for patients and surgeons alike, and it is exciting to see that the SPORT system takes us much closer to that possibility.”
almost 4pm and the shorters can only get it down a couple of cents, come on , work that magic. This should be a field day for traders.... there is no way that a PR about going from a fire side chat to a formal presentation should scare them, a move of a couple of cents on PPS today, jeez. Its a perfect storm, CE pushed back too, they have no money, no viable platform, etc, etc, etc....people have been shouting $1, sub $1 - time to deliver on that bluster.
Dr. Estape, top Gynecological Robotic surgeon in the world, said this about Titan Medical SPORT surgical robotic platform:
“The SPORT Surgical System performed beyond my expectations and I was able to complete a variety of critical surgical tasks with the necessary dexterity and precision through a single incision. The robotic instruments provided the necessary articulation, range of motion and rigidity along with 3D high-definition video on the flat panel monitor that allowed me to complete the surgery in a comfortable posture. This could be a game changer in gynecological surgery.”
AND
"“It was a privilege to lead these important studies with Titan’s single-port robotic surgery system and I am pleased that the post-surgery period has elapsed without complications. The survival of the chronic animals, along with the successful completion of other GLP acute animal and cadaver studies, demonstrates that I was able to complete the essential surgical tasks to achieve the desired results using the system. I remain very excited about the potential of Titan’s single-port robotic surgical system. Once cleared for clinical use, it may deliver single-incision surgery performance that could result in reduced trauma and faster healing for my patients.”
Dr. Estape, BEING AN EXPERT IN THIS FIELD, has more credibility then any of us - sounds like Titan has the goods when it comes to a next generation, novel SINGLE PORT surgical robotic system.
Looks like TRXC is going to get delisted from Nasdaq - what a fall. Of course anyone with a peanut for a brain saw this coming and wouldn't touch that stock.
Here is a quote from one of the worlds foremost Robotic Surgeons Arnold Advincula on TITAN MEDICAL Single Port:
Commenting on the HFE, Arnold Advincula, M.D., Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital, and the Company’s Medical Advisor on Clinical Education and Hospital Economics, said, “It was exciting to see the latest improvements with the system during my recent participation in the summative human factors studies. For any novel surgical approach to gain a strong foothold in gynecology and other surgical specialties, the system must be user-friendly without compromising technical efficacy and surgical experience.
“During the summative studies, the procedural workflow that highlighted a simple yet sophisticated design approach of the system without reinventing the wheel, was easy to learn for myself and my surgical team. The streamlined design of the system made surgical assisting seamless and safe,” he added. “I was particularly impressed with innovative features like a dual-view camera system consisting of a flexible 3D high-definition camera along with an integrated 2D high-definition camera, and insightful overlays providing valuable spatial information for the multi-articulating instruments. These features are vital for simplifying single-port robotic surgery for the surgical community predominantly familiar with multi-port approaches. I remain enthusiastic with all the progress I am seeing toward making single-incision robotic surgery a reality that will become a standard part of our minimal access surgical armamentarium.”
Under 30 days until Q4 and IDE submittal - what that means is WASH SALE for anyone that sells now and buys back within 30 days. So for those that are considering selling now or in the near future, you will HAVE TO WAIT 30 DAYS before buying back in otherwise it will be a wash sale and have negative implications for seller. If one sells and this continues to move north, they are out of luck for 30 days - the biggest question one has to ask "Is it worth the risk to unload shares now and HOPE that it goes down to $1 so they can buy back vs will this continue to move up and/or big news comes out".
If this was going to go down to $1 it would have happened already, its simple math, there is not enough leverage or position for shorters to get it down to $1. IMO, the best they could do would be to get it to $1.70 and even that would take a herculean effort. The opportunity was about 2 weeks ago and they missed it. Sure this will bounce around b/t $2 and change but that will change within 30 days.
We know Morgan Stanley has taken a position. Titan is presenting today and next week to big time investors and they are starting to figure out that in Robotics, any player will need SINGLE PORT and Titan has the goods.
IDE in Q4 (less then 30 days away) and regulatory submittal in Q4
Titan gets $35M in Funding from Aspire - good. Regulatory submission in Q4. They are much further along then any of the bigguns b/c we hear nothing from them about IDE, 510k, human clinical trials.
TITAN IS SINGLE PORT - the bigguns need it and Titan has it.
TRXC sh*t the bed so even though they were second to market, they will be the first to fold. Only reinforces the importance of a novel, next generation surgical robotic platform that is well designed and built - that is a check for Titan.
Even on this ihub board we have info on Titan from some of the top experts in the world speaking about Titan Medical SPORT platform, here is one example:
Vipul Patel, M.D., a world-renowned robotic urology surgeon from the Global Robotics Institute at Florida Hospital and the only surgeon in the world to have completed 10,000 robotic prostatectomies, said, “Although multi-port robotic prostatectomy is currently the standard of care in urology, single port robotic surgery could be the next frontier in urology and other surgical disciplines. It was exciting for me to use Titan Medical’s SPORT system at Florida Hospital Nicholson Center. The technological capabilities of the SPORT system are very encouraging and the early success in establishing feasibility is an important step in the right direction.”
THE IP IS ROCK SOLID!!!!! With Titan's patents they will own SINGLE PORT SURGERY.
It is pretty evident to me that it is:
JNJ/Titan/Verb/Auris
Another JNJ job posting for human clinical studies personnel - Titan going to begin Human Clinical Studies in Q4 - pretty solid connection, I mean coincidence, yet again...
Associate Director, Clinical Research, Digital Surgery
Johnson & Johnson
Cincinnati, OH
Apply on Johnson & Johnson Job Search - Jobs
Full-time
Johnson & Johnson's Family of Companies is recruiting for an Associate
Director, Clinical Research, Digital Surgery Platform, to be located in Cincinnati,
Ohio and may require up to 25% domestic and international travel.
Johnson
and Johnson Medical Device Companies
Ethicon’s long-term vision is to use
digital technology as part of a holistic approach to surgery across the episode
of care to enhance surgical efficiency, promote better clinical outcomes and
increase patient satisfaction. This unique position will provide scientific
leadership for Ethicon’s Digital Surgery Platform, collaborating closely with
the multi-functional evidence teams: Medical, Clinical, Pre-clinical and Health
Economics and Market Access.
Thriving on a diverse company
culture, celebrating the uniqueness of our employees and committed to
inclusion. Proud to be an equal opportunity employer. Responsibilities
include:
• Lead team of clinical research
professionals to develop and deliver appropriate global evidence generation
strategies (Pre-and Post-Market approval- studies, Investigator Initiated, Real
World Evidence) aligned to the needs of the R&D, Regulatory, Professional
Education and Commercial Digital Surgery platform
• Ensure
input and strong alignment from key regional MD CR&D leads and other
strategically important countries/regions in the development of the
clinical evidence generation strategies;
• Contribute
and support the design of appropriate clinical trials to meet the
premarket and post market needs;
• Strengthen
capability in and drive implementation of real-world evidence to deliver
cost-effective evidence solutions for Digital Surgery platform
• Identify
areas of highest impact for the Digital Surgery portfolio, create and
implement solutions that significantly impact ROI, and communicate impact
across the organization
• Develop
network with key surgeons in EU and US to assist in execution of Digital
Surgery clinical trials for registration in both regions
• Lead
teams to ensure appropriate interpretation and dissemination of all
evidence generated, based on EDS, including CSRs, abstracts, manuscripts,
etc.
• Support
clinical scientific discussions with regulatory agencies / notified bodies
to drive support of the clinical and regulatory strategy, including
proposed clinical investigations; review process of clinical evidence
generated for marketing authorization, line extensions, etc., including
during sponsor regulatory inspections;
• Provide
scientific, technical, and strategic assessment and/or oversight on New
Business Development opportunities, and support acquisition of innovative
products/devices that will position our company for future growth and
success
• Demonstrate
the ability to influence, shape and lead teams
• Develop
talent to provide strategic and scientific clinical research capability,
including responsibility for professional development of direct reports
• Have
experience in effective management of project budget processes;
• Through
transparent leadership, be a key leader in developing a high-performing
team with a global culture;
• Build
successful relationships internally and develop partnerships with key
business partners and customers/investigators
Qualifications
• A minimum of a Bachelor’s
degree in Biological Science or a related discipline is required. An
advanced degree (Master’s or PhD) is preferred
• A
minimum of 8 years of related scientific / technical experience, including
leadership / management role within Clinical Research is required
• A
minimum of 2 years of people management-related experience is required for
this role
• Experience
working in Digital Surgery/Robotics Area is strongly preferred
• Expertise
in clinical research science and processes along with a broad and
extensive understanding of product development processes, team dynamics,
related healthcare market environment, clinical trends, and global
clinical trial regulations is required
• Experience
in support of global regulatory submissions for medical devices,
biologics, or drugs (including PMA/BLA/NDA and/or their global
counterparts) is preferred
• Ability
to lead a team of clinical scientists to provide strategic and scientific
clinical research input across NPD and LCM projects is preferred
• Proven
track record of contributing to clinical programs within a clinical or
surgical research setting, on time, within budget and in compliance to
SOPs and regulations is required
• This
position will be located in Cincinnati, Ohio and may require up to 25%
domestic and international travel
Johnson & Johnson is an Affirmative Action and Equal
Opportunity Employer. All qualified applicants will receive consideration for
employment without regard to race, color, religion, sex, sexual orientation,
gender identity, age, national origin, or protected veteran status and will not
be discriminated against on the basis of disability
Primary Location
United States-Ohio-Cincinnati-
Organization
Medical Device Business Services, Inc (6029)
Job Function
Clinical Research non-MD
Requisition ID
0307190723
Titan Medical Inc - SINGLE PORT WITH HAPTIC FEEDBACK AND ADVANCED VISUALIZATION IS GAME CHANGER
Great due diligence 66 - SINGLE PORT is the future! The bigguns need to have it but it belongs to Titan Medical Inc and with the patents there is no way around.
Great info, looks like it took you a quick google search and a couple of clicks to get that link. thanks for doing that, its tough for some to put that time in.
IMO, we don't hear anything from JNJ b/c we hear it from Titan.
JNJ/Titan/Verb/Auris
Based on job postings for JNJ, they always seem to be hiring the people Titan needs 4-6 months prior to each phase of Titan development. For example, JNJ was hiring Clinical Specialist for their human clinical trials on their novel surgical robotic platform. Titan is scheduled to do human clinical trials in Q4 and JNJ was hiring clinical specialist this summer. Usually takes 4-6 months to hire someone and get them ramped up.
Just like after Titan Medical announced they signed an agreement with a worldwide supplier of end effectors for their novel surgical robotic platform - JNJ started ramping up hiring for engineers to develop end effectors for their novel surgical robotic platform
Titan is less then 30 days away from Q4 - which includes IDE approval and regulatory submittal. They just completed GLP and human factors. They will be doing human clinical trials as well as 510k submission
Interesting point - we here nothing from
Medtronic or JNJ or Stryker or any biggun about their GLP or their IDE process or their human clinical trials or their regulatory submittal.
Titan is not only the next closest platform to get approved BUT they are way ahead of Medtronic and JNJ when it comes to SINGLE PORT.
Here is a big point to make- TRXC had a FDA approved platform that completely failed - what that means is that to succeed one has to have a game changing, novel, next generation platform. Titan has it and Medtronic, JNJ and any biggun NEEDS IT!
If the shorters and mm could actually follow thru in their promise of getting this to $1 that would be fantastic. I just don’t think they can at this point, just too afraid to make that move and they don’t have the resources to do it. We shall see but it appears that they are running out of road.
IDE submittal is Q4 - less then 30 days away.
Titan has one of the world's foremost experts in IP - Jasminder Brar.
Titan is using their patents to OWN SINGLE PORT.
Intuitive’s single port might be in trouble w patent infringement of Titan’s patents
Aspire funding Titan Medical with $35M - big vote of confidence - no warrants
i think this applies to Titan Medical as well
https://www.cnn.com/2019/09/03/investing/premarket-stocks-trading/index.html
You are way, way off on Titan. Come on, IP is crucial to understanding exactly what Titan has and why it is so valuable.
Sources say Titan being courted at major investor conferences being held over the next couple of days. After the Aspire $35M funding, pretty confident Titan will get ANOTHER favorable deal on terms that is great for Titan (much like the favorable deal with Aspire).
https://titanmedicalinc.com/titan-medical-to-present-at-upcoming-september-investment-conferences/
Titan Medical will have a Market Cap of almost $250M in 3 months - it currently is at @ $70M
Here is the PR announcing $35M in funding for Titan Medical from Aspire, HUGE VOTE OF CONFIDENCE in Titan and their next generation SINGLE PORT SURGICAL ROBOTIC PLATFORM
https://www.massdevice.com/titan-medical-inks-35m-financing-deal-with-aspire-capital/
Also, no warrants attached. Based on experienced M&A people, this is a great sign for Titan and what is right around the corner.
Q4 starts in less then a month. Titan has IDE Approval in Q4 and regulatory submittal in Q4.
Good point- they just raised $3M, Titan raised $35M
Another note about Zaring, he came from Medtronic thru a acquisition, he is not a Medtronic guy. In fact he is a JNJ guy, got his big start in medtech and healthcare with JNJ
Titan medical - fully funded thru commercialization
With the $35M from an investment firm. Another $90M on the shelf and warrants going to be in the money - Titan will EASILY get the $40-50M to get to commercialization
Chad Zaring left the top post of medtronics robotic division to go to a better opportunity at Titan Medical, a start up w no money.
So either Medtronic has nothing (and we will find out on the 24th of sept) or Medtronic shows the analyst something special.
Either way, if Medtronic shows us nothing, Titans value goes way up bc medtronic will need to get competitive quick and have all three offering: multi, single port and endoluminal and it proves that zaring took the job at Titan bc medtronic has nothing
OR
Medtronic has something really impressive and shows the analysts how they can compete w intuitive and hold off jnj. They pull out all the bells and whistles and really make their platform sing. They do a first class job of showcasing their game changing platform and how it will be the future of Medtronic - AND ZARING STILL LEFT ALL THAT to go to Titan Medical inc. little ole Titan Medical w the only game changing, next generation novel SINGLE PORT surgical robotic system.
So more good news for Titan
They were able to get $35M investment for continued funding and still have $90M left on shelf. Warrants are being excercised (which is amazing with PPS where it is) and that means when it starts running, even more warrants will be exercised ( well over $33M more).
Also, based on my conversation w an M&A person in this area, the terms that Titan got is very favorable for Titan. And that the investment firm would only agree if they knew that it is an incredible oppty.
Looks like JNJ leasing some office space in Chapel Hill NC.
After bernholtz insider trading debacle, partner was telling Titan mgmt not to purchase stock due to the horrendous light bernholtz put on any Titan executive. Titan mgmt has one job and that is to complete the regulatory process (Q4 regulatory submission still on track). The partner doesn’t want any thing remotely close to even smelling like another bernholtz
No warrants attached to latest offering. We know Microline is not the end effectors manufacturers.
Q4 is less then 30 days away. Titan have IDE submittal and approval in Q4. Titan has regulatory approval in Q4.
Less then 30 days to Q4
Confirmed w Microline that they worked in Titan end effectors in 2013-2014. Titan then went and signed agreement w another supplier
JNJ/Titan/Verb/Auris
Also confirmed by Titan PR which made no mention of pushing back regulatory approval in Europe. CE mark approval still slated for Q4
IDE submittal is slated for Q4 - which is 30 days away.
JNJ/Titan/very/Auris
Auris sold for $5.7B , Titan much more valuable
Confirmed that Microline is not the end effectors supplier
We can all agree that Aspire is no bernholtz